How much biological material is required to initiate a screening project?

We typically require approximately 50-100 micrograms (μg) of purified protein or a minimum of 1 million cells expressing the target antigen per screening round. For clients with limited sample quantities, we offer antigen preparation services, which can generate sufficient antigen from sub-microgram starting material.

What deliverables will we receive after successful antibody discovery?

Clients receive: DNA sequences of unique binders; Ready-to-use expression vectors for mammalian (CHO, HEK293) or bacterial systems; 1–5 mg of purified antibody (>95% purity by SDS-PAGE, endotoxin levels <0.1 EU/mg); Comprehensive validation data: Binding affinity, cross-reactivity profiles, and functional assay results

Do you support antibody discovery against small molecules or haptens?

Absolutely. We conjugate haptens (e.g., drugs) to carrier proteins, followed by 3 rounds of pre-adsorption to eliminate carrier-specific binders.

How do I choose between immunized, naïve, and synthetic libraries for my project?

Immunized libraries excel for targets with known immunogenicity (e.g., viral spikes, cancer antigens), delivering high-affinity hits (KD <1 nM). Naïve libraries suit novel targets requiring broad epitope exploration, while synthetic libraries enable customization for challenging antigens like small molecules or cryptic epitopes.

Monoclonal Antibody Discovery Services

Q: Do you support antibody discovery against small molecules or haptens?

Absolutely. We conjugate haptens (e.g., drugs) to carrier proteins, followed by 3 rounds of pre-adsorption to eliminate carrier-specific binders.

Q: How do I choose between immunized, naïve, and synthetic libraries for my project?

Immunized libraries excel for targets with known immunogenicity (e.g., viral spikes, cancer antigens), delivering high-affinity hits (KD <1 nM). Naïve libraries suit novel targets requiring broad epitope exploration, while synthetic libraries enable customization for challenging antigens like small molecules or cryptic epitopes.

Introduction Services Species Types Cases Features FAQs Resources

Develop Monoclonal Antibodies through Phage Display

Fig.1 http://47.109.42.40:8006/images/a571d710d35123be51a790c25ab82966.jpg. (Creative Biolabs Authorized)

Phage display technology has emerged as a cornerstone of modern therapeutic antibody discovery, enabling the rapid isolation of high-affinity, fully human monoclonal antibodies (mAbs) against diverse targets. This platform exploits the genetic fusion of antibody fragments (e.g., scFv, Fab) to the minor coat protein pIII of filamentous M13 bacteriophages. By spatially coupling genotype (phage DNA) and phenotype (displayed antibody), iterative biopanning enriches antigen-specific clones from libraries exceeding 10⁹ variants.

Phage display is applied by many approved mAbs development. These therapies target oncology, inflammatory, and infectious diseases, demonstrating the platform's versatility. Critically, phage display circumvents limitations of animal-dependent methods: it bypasses immunological tolerance, screens toxic antigens, and engineers pH-dependent internalization or bispecificity. Integration with next-generation sequencing (NGS) further accelerates lead identification, reducing discovery timelines from several years to several months.

Start your monoclonal antibody discovery project now!

As pioneers in phage display technology, Creative Biolabs empowers global researchers with end-to-end monoclonal antibody discovery services tailored to your unique targets. Our platform combines species-diverse libraries (mouse, chicken, llama, and more than 20 hosts), ultra-high diversity (up to 10¹¹ clones), and affinity maturation to deliver therapeutic-grade mAbs.

Basic Process of Developing Monoclonal Antibodies through Phage Display

Our end-to-end platform integrates scalable automation and AI-driven design to deliver therapeutic-grade mAbs:

Library Construction

Biopanning & Enrichment

Binder Validation

Binder Optimization

Immune libraries

Immunized host repertoires
In vivo affinity maturation capture
Epitope-focused diversity
Time-staged sampling
Species-matched frameworks

Premade Libraries

QC-validated libraries
Curated diversity distributions
Format-ready scaffolds
Documented performance

Synthetic libraries

Semi-/fully synthetic designs
Rational CDR motif engineering
Consensus/humanized frameworks
Stability- and developability-biased diversity
De-immunization filters

Customized screening strategies for high-quality binders
Co-enrichment of stability, specificity, and affinity
Quantified enrichment trajectories for informed decisions
Binder Validation

Affinity, specificity screening
Epitope binning/competition mapping
Cell-based functional assays (neutralization potency, receptor blockade efficacy)
Ligand-competition and signaling readouts
Matrix tolerance tests (serum, pH, temperature)

Affinity maturation
Humanization/backgrafting
Developability engineering (stability, solubility)
Format/Fc engineering (isotype/effector/half-life tuning)
Format transition (scFv/Fab to IgG/multispecific)
Manufacturability optimization (expression, purification yield)

Request a project roadmap today!

Various Host Species

At Creative Biolabs, we have succeeded in generating monoclonal antibodies from various host species, including but not limited to:

Species	Species Antibody Pages
Human	Monoclonal Human Antibody Production
Monkey	Monoclonal Monkey (NHP) Antibody Production
Mouse	Monoclonal Mouse Antibody Production
Rat	Monoclonal Rat Antibody Production
Rabbit	Monoclonal Rabbit Antibody Production
Chicken	Chicken IgY Antibody Production
Camel	Monoclonal Camel Antibody Production
Shark	Monoclonal Shark Antibody Production
Cattle	Monoclonal Bovine Antibody Production
Dog	Monoclonal Canine (Dog) Antibody Production
Alligator	Monoclonal Alligator Antibody Production
Guinea Pig	Monoclonal Guinea Pig Antibody Production
Ferret	Monoclonal Ferret Antibody Production
Hamster	Monoclonal Hamster Antibody Production
Goat	Monoclonal Goat Antibody Production
Sheep	Monoclonal Sheep Antibody Production
Horse	Monoclonal Horse Antibody Production
Donkey	Monoclonal Donkey Antibody Production
Porcine	Monoclonal Porcine (Pig) Antibody Production
Duck	Monoclonal Duck Antibody Production
Zebrafish	Monoclonal Zebrafish Antibody Production
Cat	Monoclonal Cat Antibody Production

Types of Antibody Phage Display Libraries

At the core of modern antibody discovery lies the strategic selection of phage display libraries—a decision that directly impacts project success rates, therapeutic potential, and development timelines. Our platform offers three specialized library types, each engineered to address distinct biomedical challenges while ensuring optimal antigen engagement.

Immunized Libraries: Precision Targeting for Complex Antigens

Derived from B-cells of immunization donors, these libraries leverage in vivo affinity maturation to deliver antibodies with picomolar-range binding (K_D 10^-12-10^-10 M). With 85% of immunized library hits requiring no further optimization, they're ideal for:

Emerging pathogen responses
Tumor-associated antigens (PD-L1, HER2 extracellular domains)
Hard-to-drug targets (GPCRs, ion channels)

Naïve Libraries: Unlocking Broad Epitope Diversity

Constructed from healthy donors, we provide many species of premade naïve libraries with unmatched germline diversity for novel antibody discovery. Key advantages include:

72% success rate against non-immunogenic targets
CDR-H3 length variability accommodating complex epitopes
Compatibility with de novo antigen designs (e.g., DNA origami scaffolds)

Synthetic/Semi-Synthetic Libraries: Designed for Tomorrow's Challenges

Our proprietary platform combines CDR-H3 randomization with natural framework regions, achieving high functional folding rates.

Codon-Optimized Diversity: >10¹⁰ unique variants via trinucleotide doping
Epitope Steering: Pre-engineered paratopes for pockets/clefts

Find the option that works best for you— Contact us now!

Exploring Research Success: Real-Life Outcomes from Antibody Discovery

Project Snapshot

Item	Details
Objective	Discover sdAb binders to epitope peptide T1 (with specificity over controls)
Targets	Epitope peptides T1
Controls	Control peptide C1, C2, C4 Full-length control peptide C3

Outcomes Summary

Immunization and Library Quality Alpaca; 5 injections; ELISA-based titer tracking >10⁹ library diversity >90% positive accuracy	Specificity Enrichment Specificity assurance via pre-depletion on C1/C2/C3/C4 Focused recovery of T1-specific binders.
Validated Binders 2 binders specific to T1 No binding to C1/C2/C3 in binding assays

Client Value

Epitope-specific discovery with built-in counter-screens.
High-confidence immune sdAb library for rapid downselection.
Clear, validated outcomes enabling swift transition to characterization.

Unlock high-affinity antibodies faster. Get started today!

Features

Ultra-High Diversity

Immune and synthetic libraries ensure rare epitope coverage.

Epitope Mapping

Machine learning algorithms predict conformational epitopes with 90% accuracy, accelerating antibody discovery for cryptic targets like viral fusion peptides.

Cost-Effective Pilot Packages

Start your project with budget-friendly screening bundles—including basic affinity validation and sequence delivery.

Transparent QC Documentation

Receive batch-specific reports with raw NGS files, SDS-PAGE purity scans, and ELISA validation curves for every delivered antibody.

At Creative Biolabs, we redefine antibody discovery through cutting-edge phage display solutions designed for complexity and speed. Our proprietary platform ensures high epitope coverage while filtering non-specific binders via detection.

Contact us to turn undruggable targets into clinical candidates.

FAQs

Q: How much biological material is required to initiate a screening project?
A: We typically require approximately 50-100 micrograms (μg) of purified protein or a minimum of 1 million cells expressing the target antigen per screening round. For clients with limited sample quantities, we offer antigen preparation services, which can generate sufficient antigen from sub-microgram starting material.
Q: What deliverables will we receive after successful antibody discovery?
A: Clients receive:
- DNA sequences of unique binders
- Ready-to-use expression vectors for mammalian (CHO, HEK293) or bacterial systems
- 1–5 mg of purified antibody (>95% purity by SDS-PAGE, endotoxin levels <0.1 EU/mg)
- Comprehensive validation data: Binding affinity, cross-reactivity profiles, and functional assay results
Q: Do you support antibody discovery against small molecules or haptens?
A: Absolutely. We conjugate haptens (e.g., drugs) to carrier proteins, followed by 3 rounds of pre-adsorption to eliminate carrier-specific binders.
Q: How do I choose between immunized, naïve, and synthetic libraries for my project?
Immunized libraries excel for targets with known immunogenicity (e.g., viral spikes, cancer antigens), delivering high-affinity hits (KD <1 nM). A: Naïve libraries suit novel targets requiring broad epitope exploration, while synthetic libraries enable customization for challenging antigens like small molecules or cryptic epitopes.